A UAE-focused overview highlights AI-driven medical advances supported by substantial investments and collaborations aimed at improving health outcomes.

The piece warns about privacy and security risks in digitized medicine, calling for stronger safeguards to protect medical data and maintain clinical oversight while keeping healthcare accessible to people with limited digital literacy.

M42 launches Ossi, an AI platform that reduces doctors’ administrative burdens by summarizing medical histories and aiding clinical documentation, freeing clinicians to spend more time with patients.

Oracle’s new agentic AI systems illustrate broad AI capabilities in healthcare, including handling complex tasks in health-related supply chains, while acknowledging that high-stakes contexts require careful management.

Equity considerations are emphasized, urging governments and insurers to ensure AI-driven health benefits are accessible beyond the wealthy and those with extensive insurance.

Insilico Medicine, based in Masdar City, uses AI to identify potential blood cancer treatments and to develop a non-opioid pain killer, signaling AI’s role in accelerating drug discovery.

Project Cradle in the Abu Dhabi Health Department will test wearable rings to detect signs of premature birth in high-risk pregnancies, and a Whoop collaboration will study sleep, cardiovascular health, and aging, illustrating AI-enabled preventive care initiatives.

A unifying ethical stance argues that progress should be measured by how many lives are improved or saved, not merely the speed of drug discovery, underscoring real-world impact as the health AI metric.

AstraZeneca is investing $50 million in about 30 clinical trials with Cleveland Clinic Abu Dhabi, focusing on cardiovascular, renal, and metabolic diseases, and partnering with Oracle and M42 to leverage AI and real-world data for hypertension-related efforts.